Entwicklung neuer Reiseimpfstoffe – Was ist bereits zugelassen, was ist in der Pipeline?

In den letzten Jahren wurden verschiedene reisemedizinisch relevante Impfstoffe neu zugelassen. Dazu zählen neue und verbesserte Vakzine gegen Cholera, enterotoxinbildende Escherichia coli, Rotaviren, Meningokokken und Influenza. Hoffnungsvolle Impfstoffkandidaten sind die in fortgeschrittener klinischer Erprobung stehenden Impfstoffe gegen die Japanische Enzephalitis, Hepatitis E, präpandemische H5N1–Impfstoffe, ein Vierfach–Impfstoff gegen Meningokokken, eine Konjugat–Vakzine gegen den Typhus–Erreger, einige wenige Impfstoffe gegen Malaria sowie ein Impfstoff gegen den Erreger des Chikungunya–Fiebers. Dringender Bedarf an Impfstoffen besteht noch bei so bedeutenden Infektionskrankheiten wie HIV/AIDS oder Tuberkulose.

In recent years a variety of vaccines for travels abroad have been officially approved. This includes many new and improved vaccines against cholera, Escherichia coli producing enterotoxins, rotaviruses, meningococci and influenza. Promising vaccines are still being clinically tested against Japanese encephalitis, hepatitis E, pre–pandemic H5N1 vaccines, a quadruple vaccine against meningococci, a conjugate vaccine against typhoid, a few antimalarial vaccines and a vaccine against chikungunya. However, there is an urgent need for vaccines against prominent diseases such as HIV/AIDS and tuberculosis.

Key words

vaccination - travel vaccines - infectious diseases - approval - clinical testing

Literatur

• 1 Steffen R, Boppart I.. Travellers' diarrhoea.  Baillieres Clin Gastroenterol. 1987;  1 361-376
• 2 Markwalder K.. Travelers' diarrhea.  Ther Umsch. 2001;  58 367-371
• 3 Clemens JD. et al. . Field trial of oral cholera vaccines in Bangladesh: results from three–year follow–up.  Lancet. 1990;  335 270-273
• 4 Peltola H. et al. . Prevention of travellers' diarrhoea by oral B–subunit/whole–cell cholera vaccine.  Lancet. 1991;  338 1285-1289
• 5 Scerpella EG. et al. . Safety, immunogenicity, and protective efficacy of the whole–cell/recombinant B subunit (WC/rBS) oral cholera vaccine against travelers' diarrhea.  J Travel Med. 1995;  2 22-27
• 6 Wiedermann G. et al. . Double–blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B–subunit–inactivated whole cell vaccine against travelers' diarrhea (preliminary report).  J Travel Med. 2000;  7 27-29
• 7 Sack DA. et al. . Randomised, double–blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico.  Vaccine. 2007;  25 4392-4400
• 8 Vesikari T. et al. . Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double–blind controlled study.  Lancet. 2007;  370 1757-6317
• 9 Ruiz Jr. LP. Rotavirus vaccines.  N Engl J Med. 2006;  354 1747-1751
• 10 Trotter CL. et al. . Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.  Lancet. 2004;  364 365-367
• 11 Offit PA, Peter G.. Meningococcal conjugate vaccine in the UK: an update.  Lancet. 2004;  364 309-310
• 12 Lagos R. et al. . Safety and immunogenicity of a meningococcal (Groups A, C, Y, W–135) polysaccharide diphtheria toxoid conjugate vaccine in healthy children aged 2 to 10 years in Chile.  Hum Vaccin. 2005;  1 228-231
• 13 Update: Guillain–Barre syndrome among recipients of Menactra meningococcal conjugate vaccine – United States, June 2005–September 2006.  MMWR Morb Mortal Wkly Rep. 2006;  55 1120-1124
• 14 Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2–10 years with quadrivalent meningococcal conjugate vaccine (MCV4).  MMWR Morb Mortal Wkly Rep. 2008;  57 462-465
• 15 Wedege E. et al. . Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.  Clin Vaccine Immunol. 2007;  14 830-838
• 16 Hosking J. et al. . Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain–specific serogroup B meningococcal vaccine given to preteens.  Clin Vaccine Immunol. 2007;  14 1393-1399
• 17 Morley SL. et al. . Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.  Pediatr Infect Dis J. 2001;  20 1054-1061
• 18 Camaraza MA. et al. . (Immunogenecity induced by the VA–MENGOC–BC antimeningococcal vaccine against the ATCC C11. N. meningitidis strain in adolescents 12 years after being vaccinated).  Rev Cubana Med Trop. 2004;  56 26-30
• 19 Halperin SA. et al. . Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture–derived influenza vaccine in healthy adults, seniors, and children.  Vaccine. 2002;  20 1240-1247
• 20 Piedra PA. et al. . Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community–based, nonrandomized, open–label trial.  Pediatrics. 2005;  116
• 21 Piedra PA. et al. . Trivalent live attenuated intranasal influenza vaccine administered during the 2003–2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.  Pediatrics. 2007;  120
• 22 Belshe RB. et al. . Live attenuated versus inactivated influenza vaccine in infants and young children.  N Engl J Med. 2007;  356
• 23 Treanor JJ. et al. . Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.  N Engl J Med. 2006;  354 1343-1351
• 24 Leroux–Roels I. et al. . Antigen sparing and cross–reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.  Lancet. 2007;  370 580-589
• 25 Defraites RF. et al. . Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens.  Am J Trop Med Hyg. 1999;  61 288-293
• 26 Lyons A. et al. . A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.  Vaccine. 2007;  25 3445-3453
• 27 Tauber E. et al. . Safety and immunogenicity of a Vero–cell–derived, inactivated Japanese encephalitis vaccine: a non–inferiority, phase III, randomised controlled trial.  Lancet. 2007;  370 1847-1853
• 28 Gerolami R, Moal V, Colson P.. Chronic hepatitis E with cirrhosis in a kidney–transplant recipient.  N Engl J Med. 2008;  358
• 29 Peron JM. et al. . Liver histology in patients with sporadic acute hepatitis E: a study of 11 patients from South–West France.  Virchows Arch. 2007;  450 405-410
• 30 Kamar N. et al. . Hepatitis E virus and chronic hepatitis in organ–transplant recipients.  N Engl J Med. 2008;  358 811-817
• 31 Shrestha MP. et al. . Safety and efficacy of a recombinant hepatitis E vaccine.  N Engl J Med. 2007;  356 895-903
• 32 Snape MD. et al. . Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.  Jama. 2008;  299 173-184
• 33 Lin FY. et al. . The efficacy of a Salmonella typhi Vi conjugate vaccine in two–to–five–year–old children.  N Engl J Med. 2001;  344 1263-1269
• 34 Aponte JJ. et al. . Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.  Lancet. 2007;  370 1543-1551
• 35 Levitt NH. et al. . Development of an attenuated strain of chikungunya virus for use in vaccine production.  Vaccine. 1986;  4 157-162
• 36 Edelman R. et al. . Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI–GSD–218.  Am J Trop Med Hyg. 2000;  62 681-685
• 37 Whitehead SS. et al. . Prospects for a dengue virus vaccine.  Nat Rev Microbiol. 2007;  5 518-528
• 38 Kanesa–thasan N. et al. . Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.  Vaccine. 2001;  19 3179-3188
• 39 Arroyo J. et al. . ChimeriVax–West Nile virus live–attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.  J Virol. 2004;  78 12497-12507
• 40 Hall RA, Khromykh AA.. ChimeriVax–West Nile vaccine.  Curr Opin Mol Ther. 2007;  9 498-504
• 41 Yates J.. Traveler's diarrhea.  Am Fam Physician. 2005;  71 2095-2100

Korrespondenz